Thesis

60 Part I Chapter 2 41. Mari C, Catafau A, Carrio I. Bone scintigraphy andmetabolic disorders. Q J Nucl Med. 1999; 43: 259-267. 42. Hain SF, Fogelman I. Nuclear medicine studies in metabolic bone disease. Semin Musculoskelet Radiol. 2002; 6: 323-329. 43. Cachovan M, Vija AH, Hornegger J, Kuwert T. Quantification of 99mTc-DPD concentration in the lumbar spine with SPECT/CT. EJNMMI Res. 2013; 3: 45. 44. de Graaf P, Schicht IM, Pauwels EK, te Velde J, de Graeff J. Bone scintigraphy in renal osteodystrophy. J Nucl Med. 1978; 19: 1289-1296. 45. de Jonge FA, Pauwels EK, Hamdy NA. Scintigraphy in the clinical evaluation of disorders of mineral and skeletal metabolism in renal failure. Eur J Nucl Med. 1991; 18: 839-855. 46. ICRP. Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007. Ann ICRP. 2008; 38: 1-197. 47. Doran MG, Spratt DE, Wongvipat J, Ulmert D, Carver BS, Sawyers CL et al. Cabozantinib resolves bone scans in tumor-naive mice harboring skeletal injuries. Mol Imaging. 2014; 13: doi: 10.2310/7290.2014.00026. 48. Lassmann M, Treves ST. Paediatric radiopharmaceutical administration: harmonization of the 2007 EANM paediatric dosage card (version 1.5.2008) and the 2010 North American consensus guidelines. Eur J Nucl Med Mol Imaging. 2014; 41: 1036-41. 49. Parker JA, GrahamLS, Royal HD, Todd-Pokropek AE, Daube-Witherspoon ME, Yester MV. SNM Procedure Guideline for General Imaging v6.0. 2010. In: Society of Nuclear Medicine and Molecular Imaging Procedure Standards. 2003. http://snmmi.files.cms-plus. com/docs/General_Imaging_Version_6.0.pdf. Accessed 15/11/2015. 50. Busemann Sokole E, Plachcinska A, Britten A, Lyra Georgosopoulou M, Tindale W, Klett R. Routine quality control recommendations for nuclear medicine instrumentation. Eur J Nucl Med Mol Imaging. 2010; 37: 662-71. 51. BrownML, O’Connor MK, Hung JC, Hayostek RJ. Technical aspects of bone scintigraphy. Radiol Clin North Am. 1993; 31: 721-730. 52. Schirrmeister H, Glatting G, Hetzel J, Nussle K, Arslandemir C, Buck AK, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001; 42: 1800-1804. 53. Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA et al. Procedure Guideline for SPECT/CT Imaging 1.0. J Nucl Med. 2006; 47: 1227-1234. 54. Palmedo H, Marx C, Ebert A, Kreft B, Ko Y, Turler A et al. Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging. 2014; 41: 59-67. 55. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011; 17: 4854-61. 56. Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP publication 53). Ann ICRP. 1998; 28: 1-126. 57. Mettler FA, Jr. , Huda W, Yoshizumi TT, Mahesh M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology. 2008; 248: 254-63. 58. Brix G, Nekolla EA, Borowski M, Nosske D. Radiation risk and protection of patients in clinical SPECT/CT. Eur J Nucl Med Mol Imaging. 2014; 41 Suppl 1: S125-36.

RkJQdWJsaXNoZXIy MjY0ODMw